Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Sarepta Therapeutics entered into a settlement agreement with REGENXBIO and the University of Pennsylvania to resolve patent disputes related to AAVrh74-based gene therapies, including ELEVIDYS. Sarepta will pay a $39 million lump sum and receive broad releases and covenants not to sue covering spe…
Sarepta Therapeutics, Inc.: Entered Settlement Agreement With Regenxbio, UPenn Trustees, and Catalent >SRPT
REGENXBIO and the University of Pennsylvania entered into a Settlement Agreement with Sarepta Therapeutics and Catalent to resolve patent litigation tied to AAVrh74-based gene therapies, including Elevidys. Sarepta will pay REGENXBIO $39.0 million within 10 days of the effective date, and all ongoi…